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Middle ear cholesteatoma is characterized by the presence
of keratinizing epithelium, which may be a congenital
remnant or due to migration from the eardrum epithelium
into the mesotympanum. Cholesteatoma epithelium has
different characteristics to normal epidermal epithelium, in
that it is hyperproliferative and has locally invasive growth
and induced resorption of auditory ossicles and surrounding
bone tissue [1]. Recent research has attributed an important
role in keratinocyte proliferation to numerous growth factors
and cytokines, one of which is epidermal growth factor
(EGF) and its receptor, EGF-receptor (EGFR). EGFR is a
170 kd to 180 kd glycoprotein with an intrinsic tyrosine-
specific protein kinase that is stimulated by binding its
stimulator (EGF) and transforming growth factor-alpha
(TGF-α) [2]. The density of EGFR in a cell is related to the
state of differentiation and the ability of the keratinocytes to
differentiate [3]. EGFR expression in keratinocytes may be
considered a marker indicating that the cells are in a state of
proliferation and poor terminal differentiation [4]. Using
immunohistochemistry, we investigated the presence of
EGFR in cholesteatoma and delineated the role that EGFR
may play in the growth of cholesteatoma.
MATERIALS AND METHODS
Cholesteatoma specimens were obtained from 29 patients
(mean age, 38 years; range, 19–51 years) who underwent
middle ear surgery at the Department of Otolaryngology,
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Middle ear cholesteatoma is destructive to auditory ossicles and temporal bone, and treatment usually
includes surgical removal of all epithelial content in the tympanomastoid cavity. Epidermal growth factor
receptor (EGFR) is a 170 kd to 180 kd transmembrane glycoprotein and its distribution density is related
to the ability of the keratinocytes to differentiate and their state of differentiation. We used the avidin-
biotin complex technique and EGFR monoclonal antibody to evaluate the expression of EGFR in 29 cases
of cholesteatoma and 34 samples of normal postauricular skin. Of patients with cholesteatoma, 79% (23
cases) had EGFR-positive cells in the basal layer, 66% (19 cases) in the parabasal layer, and 62% (18 cases)
in the upper layer of the epithelial tissue. Among patients with normal postauricular skin, 85% (29 cases)
had EGFR-positive cells in the basal layer, 79% (27 cases) in the parabasal layer, and 79% (27 cases) in
the upper layer of the epithelial tissue. No statistical difference in EGFR expression between each layer
of cholesteatoma and postauricular skin was noted. However, there was an intensity gradient of positive
EGFR immunoreactivity from the basal to the higher layers in cholesteatoma. Our results showed that
the distribution of EGFR in middle ear cholesteatoma is not deranged, but is similar to that in normal
skin tissue.
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Kaohsiung Medical University Hospital, Taiwan. Skin from
the postauricular area of 34 patients (mean age, 43 years;
range 19–67 years) who underwent middle ear surgery for
chronic otitis media was collected during the same period
to provide a control group. Immediately after surgery,
tissue specimens were fixed in formalin, embedded in
paraffin, stained with hematoxylin and eosin, and examined
histopathologically.
Immunohistochemical staining for EGFR
Specimens were fixed in 10% buffered formalin solution
overnight, subjected to dehydration and paraffin
embedding, and sliced into 4 µm sections. After
deparaffinization and washing, endogenous peroxidase in
sections was inhibited using 0.3% methanolic hydrogen
peroxide and then blocked with 10% normal horse serum
and 1% bovine serum albumin for 30 minutes. After a brief
rinse, the sections were incubated with EGFR monoclonal
antibody (1:20, BioGenex Laboratories Inc, San Ramon, CA,
USA) at room temperature for 120 minutes. The sections
were washed in phosphate-buffered saline, incubated for
30 minutes with biotinylated anti-mouse immunoglobulin
(Ig) G, and then treated with avidin-biotin complex for 30
minutes. Finally, 3-3’-diaminobenzidine was applied as a
chromogen and sections were visualized after
counterstaining with Mayer’s hematoxylin. EGFR labeling
(in brown color) was considered positive if there was at
least one EGFR-positive cell in each epithelial layer. EGFR
expression in breast cancer cells was used as a positive
control and the omission of primary antibody was used as
a negative control. The difference in distribution patterns in
the basal, parabasal, and upper layers of the epithelial
tissue between the two groups was assessed using the Chi-
squared test.
RESULTS
EGFR-positive cells in breast cancer sections were brown in
color. Two patterns of immunoreactivity were recognized:
cell-membrane staining and granular cytoplasmic staining
(Figure 1). There was no recognizable brown color in sections
where the primary antibody had been omitted.
EGFR expression in cholesteatoma epithelium was
mainly associated with the cell membrane and was localized
in the basal, parabasal, and upper layers (Figure 2), similar
to the pattern in the positive control (Figure 1). Of the 29
cases of cholesteatoma, 23 (79%) were positive for EGFR
expression in the basal layer of the epithelium. Nineteen
cases (66%) were positive for EGFR in the parabasal layer
and 18 cases (62%) in the upper layer. The immunoreactivity
was most intense in the basal layer, and decreased in
distribution towards the upper layer (Table 1).
EGFR expression in postauricular skin was localized in
the basal to upper layers (Figure 3). Of the 34 normal
postauricular skin samples, 29 (85%) were positive for
EGFR expression in the basal layer, 27 (79%) in the parabasal
layer, and 27 (79%) in the upper layer (Table 2). The
distribution of EGFR-positive cells decreased from the basal
layer towards the superficial layer, but no difference between
the parabasal and upper layers was observed.
Figure 1. (A) Epithelial growth factor receptor (EGFR) immunostaining
in breast cancer (positive control). Positive staining is judged by the
brown color in sections. Immunoreactive sites are recognized in the cell
membrane (arrow) and granular cytoplasm. (B) When primary antibody
for EGFR is omitted in the same section, there is no recognizable brown
color. (Original magnification × 220.)
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There was EGFR expression in more cells in normal
postauricular skin than in cholesteatoma skin, but there
was no statistically significant difference in each layer
between the two groups (Table 3).
DISCUSSION
Histologically, cholesteatoma is composed of an
accumulation of desquamated keratin arising from
squamous epithelium. The growth of cholesteatoma seems
not to cease and may be recurrent for many years
Figure 2. (A) Epithelial growth factor receptor (EGFR) immunostaining
in cholesteatoma epithelium. Positive staining is associated with the cell
membrane and is found in the basal, parabasal, and upper layers of the
epithelium (arrows). (B) The same section with omission of EGFR
monoclonal antibody immunostaining. (Original magnification × 220.)
Figure 3. (A) Positive immunostaining for epithelial growth factor
receptor (EGFR) in normal postauricular skin. EGFR-positive cells are
observed in the basal (arrow), parabasal, and upper layers of the epithelium.
(B) The same section with omission of EGFR monoclonal antibody
immunostaining. (Original magnification × 40.)
Table 1. Distribution of epithelial growth factor receptor in
middle ear cholesteatoma (29 cases)
Epithelium Strongly positive/positive Negative
n (%) n (%)
Upper layer 18 (62) 11 (38)
Parabasal layer 19 (66) 10 (34)
Basal layer 23 (79) 6 (21)
Total 23 (79) 6 (21)
postoperatively unless the cholesteatoma is totally
eradicated. The clinical characteristics of cholesteatoma
indicate that it has hyperproliferative ability, and autocrine
growth stimulation by TGF-α and EGFR may contribute to
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the unrestrained growth of cholesteatoma epithelium in the
middle ear cavity [5,6]. EGFR is a transmembrane
glycoprotein, with a molecular weight of about 170 kd,
involved in EGF- and TGF-α-stimulated cell proliferation.
It activates tyrosine protein kinase, resulting in
phosphorylation of itself and other substrates, leading to
cell proliferation. In human skin, EGFR is found in
keratinocytes, especially in the basal layer, as well as in
sebocytes, smooth muscle cells (including the arrectores
pilorum), and myoepithelial cells [7]. In this study, we used
immunohistochemical staining to identify EGFR distribution
in cholesteatoma epithelium.
In our study, the basal layers of cholesteatoma epithelium
exhibited strong expression of EGFR, with less expression
in the higher layers. In the epithelium of normal skin, an
intensity gradient of positive EGFR immunoreactivity was
observed from the basal to higher layers. The similar
expression of EGFR in cholesteatoma and postauricular
skin shows that the orderly pattern of positive EGFR
immunoreactivity is not deranged in cholesteatoma
epithelium. Groves et al examined EGFR expression in a
variety of benign and malignant epithelial neoplasms, and
found that there was an ordered pattern in benign tumors
but a loss of membrane labeling and cytoplasmic
accumulation of EGFR in malignant tumors [8]. EGFR
dysregulation may be important in the development of
epithelial malignancy.
There was no significant difference in EGFR distribution
in cholesteatoma and postauricular skin in our study
compared with other reports in the literature. Ergun et al [5]
and Uno and Saito [9] reported a significant increase in
EGFR in cholesteatoma compared to postauricular skin.
Bujia et al reported heterogeneity in EGFR expression in
different parts of cholesteatoma [10], which suggests the
presence of aberrant regulation. Later, Bujia et al used
enzyme-linked immunosorbent assays (ELISAs) to confirm
that the abnormal growth of cholesteatoma epithelium was
reflected in aberrant expression of EGFR [11]. Relative
differences have been reported in the intensity of EGFR
expression in epidermal layers (basalis > spinosum >
granulosum > corneum) [12]. The results of our study are
different, possibly because the incubation time for sections
and monoclonal antibody was longer than in previous
reports: 120 minutes compared to 30 minutes [5,10]. The
longer incubation time may increase the binding of
monoclonal antibody to receptors in the superficial layer of
normal skin, leading to changes in positive rates. We divided
the intensity of immunohistochemical staining into negative
and positive groups (including strongly positive
immunoreactivity). Uno and Saito [9] and Bujia et al [10]
included an additional subgroup for weakly or questionably
positive immunoreactivity. Our study may have categorized
weakly positive staining in normal skin epidermis into the
positive group, resulting in no statistical difference between
cholesteatoma and postauricular skin.
Kojima et al reported an increase in the rates of
proliferation and apoptotic cell death in cholesteatoma
epidermis [13]. The hyperproliferative epithelium of
cholesteatoma may have higher metabolic status to degrade
the receptor or down-regulate EGFR by cholesteatoma-
produced EGF and TGF-α. The subepithelial inflammation
and probable high turnover rate in cholesteatoma epithelium
may also stimulate cell apoptosis. Uno and Saito subdivided
cholesteatoma into “active” and “inactive” types [9], based
on the thickness of the cholesteatoma epithelium, the amount
of granulation in the cholesteatoma subepithelium, and the
degree of otorrhea symptoms. They reported that there was
stronger immunoreactivity in active than in inactive
cholesteatoma. There may have been a high proportion
of inactive cholesteatoma and apoptosis in our specimens,
causing no significant difference in EGFR expression
Table 2. Distribution of epithelial growth factor receptor in
normal postauricular skin (34 cases)
Epithelium Strongly positive/positive Negative
n (%) n (%)
Upper layer 27 (79) 7 (21)
Parabasal layer 27 (79) 7 (21)
Basal layer 29 (85) 5 (15)
Total 29 (85) 5 (15)
Table 3. Comparison of positive staining for epithelial
growth factor receptor in middle ear cholesteatoma and
postauricular skin
Cholesteatoma Postauricular skin
n (%) n (%)
Upper layer 18 (62) 27 (79)*
Parabasal layer 19 (66) 27 (79)*
Basal layer 23 (79) 29 (85)*
*p > 0.05.
Epidermal growth factor receptor in cholesteatoma
501Kaohsiung J Med Sci October 2003 • Vol 19 • No 10
between cholesteatoma and normal skin tissue.
Park et al found that deep meatal skin has different
characteristics from retroauricular skin in Mongolian gerbils,
with positive staining for EGFR in the suprabasal layer
of experimental cholesteatoma induced by ligation of the
external auditory canal [14]. There are many theories of
how the epithelium grows into the middle ear, including
the metaplasia hypothesis, the retraction theory, and direct
ingrowth from eardrum perforation. The squamous
epithelium that migrates into the middle ear cavity uses the
granulation tissue and organized effusion as a bridge,
resulting in migration and formation of cholesteatoma [15].
Apart from the proliferation effect of EGFR, EGFR also
supports both cell-cycle progression and survival of
keratinocytes [16]. EGFR may help keratinocytes to survive
and proliferate in different growth conditions, such as
middle ear mucosa or even bony substrate. Kojima et al
used in situ hybridization to show that there was strong
signal expression of EGFR mRNA in all epithelial layers of
cholesteatoma, but only in part of the basal layer of normal
external ear canal skin [17]. Whether the cholesteatoma
epithelium has more hyperproliferative ability than normal
skin, as proposed by Anniko and Mendel [1], is controversial.
Shieh et al used immunochemistry to investigate
proliferating cell nuclear antigen in cholesteatoma and to
evaluate its proliferative activity [18]. Their report indicates
that cholesteatoma has a similar proliferative activity to
normal postauricular skin, and that cholesteatoma itself is
not a tumor despite its clinical behavior, which is similar to
neoplastic cells.
EGFR is not the only factor involved in the development
of cholesteatoma. Studies implicate a potential idiopathic
response to both internal events and external stimuli with
the induction of hyperproliferative cells in the cholesteatoma
epithelium. Internal stimuli such as heat shock proteins or
external stimuli such as cytokines released by inflammatory
cells are reported to be associated with the regulation of
cellular proliferation or apoptosis in cholesteatoma [19,20].
Although there was no significant difference in EGFR
expression between cholesteatoma and postauricular skin
in our study, other factors may be meaningful. It is hoped
that further study will provide better understanding of
these interactions.
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